Mitchell Finkel supports preventive services clients on United States federal and state policy.
Mitchell has expertise on government-regulated market policy and access (e.g., Medicare, Medicaid, Federally Qualified Health Centers) coverage and reimbursement policies for preventive products. Mitchell assists clients in understanding the implications of Advisory Committee on Immunization Practices, United States Preventive Services Task Force and Health Resource Service Administration Recommendations. Prior to joining Avalere, Mitchell interned at Todd Strategy, where he researched and summarized regulatory and legislative issues affecting the pharmaceutical and bio-tech sectors.
Mitchell has a BS in public health from the George Washington University. Mitchell is a current member of the American Academy of Professional Coders and received his Certified Professional Biller certificate.
Authored Content
A new Avalere analysis reaffirms 2021 findings that first identified variability in Medicaid physician office and pharmacy vaccine reimbursement policies.
In this eBook, Avalere experts discuss the evolving vaccines ecosystem and analyze key policy issues affecting vaccines manufacturers.
In a new white paper, Avalere considers key questions related to strain selection, ACIP recommendation, and coverage and reimbursement of adult combination vaccines in development.
Following policy changes addressing vaccine coverage gaps, stakeholders are focusing on provider financial and administrative barriers to vaccination.
The IRA expanded vaccine access, but variations in federal policies governing vaccine coverage requirements and implementation remain
At its June meeting, ACIP reviewed data on several currently marketed and novel immunizations, highlighting the committee's focus on cost, accessibility, and equity.
19% of people enrolled in the US commercial insurance market will belong to a health plan that must count copay assistance toward patient cost sharing by 2024.
The proposed vaccine definition would have a significant market impact on novel immunizations such as preventive immunoglobulins and therapeutic vaccines.
A new Avalere analysis identified variability in Medicaid physician office, pharmacy, and Federally Qualified Health Centers vaccine reimbursement policies.
Avalere identified 19 states that must change their Medicaid vaccine policies to comply with the IRA’s requirement that states cover all recommended vaccines without cost sharing.
Tune into the second episode in our video series focused on Respiratory Syncytial Virus (RSV) prevention. In this segment, Avalere experts discuss RSV prevention products currently in development, specifically maternal immunizations and pediatric vaccines.
Tune into the second episode in our video series focused on Respiratory Syncytial Virus (RSV) prevention. In this segment, Avalere experts discuss RSV prevention products currently in development, specifically maternal immunizations and pediatric vaccines.
Tune into the first episode in our video series focused on Respiratory Syncytial Virus (RSV) prevention. In this segment, Avalere experts discuss how innovative offerings in the pediatric RSV immunization market will fit within the continuum of care and how the RSV preventive market will grow in the upcoming years.
Numerous novel respiratory syncytial virus (RSV) preventive products, including vaccines and monoclonal antibodies (mAbs), are in late-stage clinical development. Consequently, the RSV prevention landscape is expected to transform in the coming years. Adequate preparation to incorporate the use of these new tools should consider the regulatory and recommendation pathways and their implications for coverage and reimbursement.
The IRA will expand adult vaccine access by mandating coverage without cost sharing for all adult vaccines in Medicare Part D and Medicaid.
The COVID-19 pandemic identified gaps in US public health infrastructure and resources, prompting policy proposals and opportunities for stakeholder engagement.
A new claims-based analysis from Avalere examined vaccine uptake among low-income adolescents enrolled in Medicaid Managed Care and found a 26% decline in routine vaccinations when comparing March–October 2019 to the same period in 2020.
In November 2020, the Food and Drug Administration (FDA) granted Emergency Use Authorization (EUA) to COVID-19 monoclonal antibodies for treatment of mild-to-moderate COVID-19 infection.
The majority of state legislatures are currently in session, and many states are taking steps to address prescription drug spending and prices through a range of legislative proposals. While states have historically focused on price transparency, state policymakers are now moving beyond those measures to more directly control prescription drug prices through reference pricing, affordability review boards setting upper payment limits, and other price control mechanisms.
Amid the continuing pandemic and calls for healthcare reform, the new administration seeks to confront the myriad public health issues facing our country today.
On January 21, the Biden administration released its National Strategy for the COVID-19 Response and Pandemic Preparedness. The plan highlights numerous actions that the administration intends to implement as it assumes responsibility in the fight against COVID-19.
Tune into another episode of Get the Facts on COVID-19. In this segment, our vaccines experts discuss state COVID-19 vaccine distribution plans, distribution challenges, and what this space might look like as the vaccines become more widely available.
As the novel coronavirus disease (COVID-19) continues to change daily life, concerns about the impact on global supply chains and possible drug shortages have increased. Additionally, changes to FDA processes may limit its ability to perform essential drug related activities.
New analysis from Avalere finds that states currently covering non-mandatory adult populations who choose to participate in the Healthy Adult Opportunity (HAO) initiative may need to generate up to 8% in Medicaid savings to keep spending below new capped funding levels.